UY28067A1 - Formulaciones de deposito de liberacion controlada - Google Patents
Formulaciones de deposito de liberacion controladaInfo
- Publication number
- UY28067A1 UY28067A1 UY28067A UY28067A UY28067A1 UY 28067 A1 UY28067 A1 UY 28067A1 UY 28067 A UY28067 A UY 28067A UY 28067 A UY28067 A UY 28067A UY 28067 A1 UY28067 A1 UY 28067A1
- Authority
- UY
- Uruguay
- Prior art keywords
- controlled release
- beneficial agent
- compositions
- deposit formulations
- polymer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
- A61K9/204—Polyesters, e.g. poly(lactide-co-glycolide)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Se describen métodos y composiciones para administrar en forma sistémica o local un agente beneficioso a un sujeto, e incluyen, por ejemplo, composiciones de depósito en gel que pueden inyectarse e una ubicación deseada y que pueden proveer la liberación controlada de un agente beneficioso durante un período prolongado de tiempo. Las composiciones incluyen un polímero biocompatible, un solvente biocompatible que tiene baja miscibilidad en agua que forma un jul viscoso con el polímero y limita la capacitación de agua por él implante, y un agente beneficioso.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US42442802P | 2002-11-06 | 2002-11-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY28067A1 true UY28067A1 (es) | 2003-12-31 |
Family
ID=32312806
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY28067A UY28067A1 (es) | 2002-11-06 | 2003-11-06 | Formulaciones de deposito de liberacion controlada |
Country Status (26)
Country | Link |
---|---|
US (1) | US7368126B2 (es) |
EP (1) | EP1581181B1 (es) |
JP (1) | JP2006508127A (es) |
KR (1) | KR20050088288A (es) |
CN (1) | CN1713890A (es) |
AR (1) | AR041913A1 (es) |
AT (1) | ATE418323T1 (es) |
AU (1) | AU2003295409B2 (es) |
BR (1) | BR0315304A (es) |
CA (1) | CA2504608C (es) |
CL (1) | CL2003002277A1 (es) |
DE (1) | DE60325511D1 (es) |
EC (2) | ECSP055838A (es) |
HK (1) | HK1085387A1 (es) |
MA (1) | MA27523A1 (es) |
MX (1) | MXPA05004927A (es) |
MY (1) | MY140155A (es) |
NO (1) | NO20052635L (es) |
NZ (1) | NZ539810A (es) |
PE (1) | PE20040675A1 (es) |
PL (1) | PL377333A1 (es) |
RU (1) | RU2355385C2 (es) |
TW (1) | TW200503774A (es) |
UY (1) | UY28067A1 (es) |
WO (1) | WO2004043432A2 (es) |
ZA (1) | ZA200504529B (es) |
Families Citing this family (142)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5869079A (en) * | 1995-06-02 | 1999-02-09 | Oculex Pharmaceuticals, Inc. | Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents |
US20060280774A1 (en) * | 1995-06-02 | 2006-12-14 | Allergan, Inc. | Compositions and methods for treating glaucoma |
CA2685349C (en) * | 1999-11-15 | 2013-09-17 | Bio Syntech Canada Inc. | Temperature-controlled and ph-dependant self-gelling biopolymeric aqueous solution |
US20030158302A1 (en) * | 1999-12-09 | 2003-08-21 | Cyric Chaput | Mineral-polymer hybrid composition |
WO2001041821A1 (en) * | 1999-12-09 | 2001-06-14 | Biosyntech Canada Inc. | Mineral-polymer hybrid composition |
US20050042194A1 (en) | 2000-05-11 | 2005-02-24 | A.P. Pharma, Inc. | Semi-solid delivery vehicle and pharmaceutical compositions |
NZ523763A (en) * | 2000-06-29 | 2005-02-25 | Biosyntech Canada Inc | Compostion and method for the repair and regeneration of cartilage and other tissues |
US6726918B1 (en) | 2000-07-05 | 2004-04-27 | Oculex Pharmaceuticals, Inc. | Methods for treating inflammation-mediated conditions of the eye |
US20040018228A1 (en) * | 2000-11-06 | 2004-01-29 | Afmedica, Inc. | Compositions and methods for reducing scar tissue formation |
US20040091540A1 (en) * | 2000-11-15 | 2004-05-13 | Desrosiers Eric Andre | Method for restoring a damaged or degenerated intervertebral disc |
ES2250504T3 (es) | 2000-11-29 | 2006-04-16 | Allergan Inc. | Prevencion del rechazo de injerto en el ojo. |
US20070196415A1 (en) * | 2002-11-14 | 2007-08-23 | Guohua Chen | Depot compositions with multiple drug release rate controls and uses thereof |
DE60239556D1 (de) * | 2001-11-14 | 2011-05-05 | Durect Corp | Katheterinjizierbare depotzusammensetzungen und deren verwendung |
US20040001889A1 (en) | 2002-06-25 | 2004-01-01 | Guohua Chen | Short duration depot formulations |
MXPA05001244A (es) | 2002-07-31 | 2005-06-08 | Alza Corp | Composiciones de deposito de polimero multimodal inyectable y usos de las mismas. |
AU2002359397B2 (en) * | 2002-07-31 | 2009-01-29 | Durect Corporation | Injectable depot compositions and uses thereof |
US7731947B2 (en) | 2003-11-17 | 2010-06-08 | Intarcia Therapeutics, Inc. | Composition and dosage form comprising an interferon particle formulation and suspending vehicle |
US20050048099A1 (en) | 2003-01-09 | 2005-03-03 | Allergan, Inc. | Ocular implant made by a double extrusion process |
JP2006521897A (ja) * | 2003-03-31 | 2006-09-28 | アルザ・コーポレーション | 内部圧力を放散する手段を備える浸透ポンプ |
DE602004015755D1 (de) * | 2003-03-31 | 2008-09-25 | Alza Corp | Nicht wässrige einphasige visköse vehikel und formulierungen die diese vehikel verwenden |
US20050010196A1 (en) * | 2003-03-31 | 2005-01-13 | Fereira Pamela J. | Osmotic delivery system and method for decreasing start-up times for osmotic delivery systems |
US20070184084A1 (en) * | 2003-05-30 | 2007-08-09 | Guohua Chen | Implantable elastomeric caprolactone depot compositions and uses thereof |
CN1822816A (zh) * | 2003-05-30 | 2006-08-23 | 阿尔萨公司 | 可植入的弹性体储库组合物、其用途以及制备方法 |
US20050106214A1 (en) * | 2003-11-14 | 2005-05-19 | Guohua Chen | Excipients in drug delivery vehicles |
US8673341B2 (en) | 2004-04-30 | 2014-03-18 | Allergan, Inc. | Intraocular pressure reduction with intracameral bimatoprost implants |
US8529927B2 (en) * | 2004-04-30 | 2013-09-10 | Allergan, Inc. | Alpha-2 agonist polymeric drug delivery systems |
US8722097B2 (en) | 2004-04-30 | 2014-05-13 | Allergan, Inc. | Oil-in-water method for making polymeric implants containing a hypotensive lipid |
US7993634B2 (en) | 2004-04-30 | 2011-08-09 | Allergan, Inc. | Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods |
US9498457B2 (en) | 2004-04-30 | 2016-11-22 | Allergan, Inc. | Hypotensive prostamide-containing biodegradable intraocular implants and related implants |
US8685435B2 (en) | 2004-04-30 | 2014-04-01 | Allergan, Inc. | Extended release biodegradable ocular implants |
US20050244469A1 (en) | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Extended therapeutic effect ocular implant treatments |
WO2005107708A1 (en) | 2004-04-30 | 2005-11-17 | Allergan, Inc. | Biodegradable intravitreal tyrosine kinase inhibitors implants |
US8119154B2 (en) | 2004-04-30 | 2012-02-21 | Allergan, Inc. | Sustained release intraocular implants and related methods |
US20050244463A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Sustained release intraocular implants and methods for treating ocular vasculopathies |
US7799336B2 (en) | 2004-04-30 | 2010-09-21 | Allergan, Inc. | Hypotensive lipid-containing biodegradable intraocular implants and related methods |
US20050244458A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Sustained release intraocular implants and methods for treating ocular neuropathies |
US8425929B2 (en) | 2004-04-30 | 2013-04-23 | Allergan, Inc. | Sustained release intraocular implants and methods for preventing retinal dysfunction |
US20050266087A1 (en) * | 2004-05-25 | 2005-12-01 | Gunjan Junnarkar | Formulations having increased stability during transition from hydrophobic vehicle to hydrophilic medium |
CA2575988C (en) | 2004-08-04 | 2014-02-18 | Brookwood Pharmaceuticals, Inc. | Methods for manufacturing delivery devices and devices thereof |
US20080038316A1 (en) * | 2004-10-01 | 2008-02-14 | Wong Vernon G | Conveniently implantable sustained release drug compositions |
KR101341359B1 (ko) * | 2004-10-01 | 2013-12-13 | 램스코르 인코포레이티드 | 편리하게 이식가능한 서방형 약물 조성물 |
US8541413B2 (en) * | 2004-10-01 | 2013-09-24 | Ramscor, Inc. | Sustained release eye drop formulations |
US9993558B2 (en) | 2004-10-01 | 2018-06-12 | Ramscor, Inc. | Sustained release eye drop formulations |
AR052155A1 (es) * | 2004-12-14 | 2007-03-07 | Novartis Ag | Compuestos organicos |
WO2006065951A2 (en) * | 2004-12-15 | 2006-06-22 | Qlt Usa, Inc. | Sustained delivery formulations of octreotide compounds |
US20060141040A1 (en) * | 2004-12-23 | 2006-06-29 | Guohua Chen | Injectable non-aqueous suspension |
WO2006083761A2 (en) | 2005-02-03 | 2006-08-10 | Alza Corporation | Solvent/polymer solutions as suspension vehicles |
US11246913B2 (en) | 2005-02-03 | 2022-02-15 | Intarcia Therapeutics, Inc. | Suspension formulation comprising an insulinotropic peptide |
WO2006123360A2 (en) * | 2005-03-01 | 2006-11-23 | Sun Pharmaceutical Industries Limited | Microspheres containing octreotide acetate |
BRPI0613731A2 (pt) * | 2005-07-12 | 2011-02-01 | Renovo Ltd | composição farmacêutica, recipiente enchido previamente, bem como uso de um açúcar para aprimorar a recuperação e/ou aumentar a atividade biológica de um membro da superfamìlia tgf-beta |
US20070027105A1 (en) | 2005-07-26 | 2007-02-01 | Alza Corporation | Peroxide removal from drug delivery vehicle |
US8852638B2 (en) * | 2005-09-30 | 2014-10-07 | Durect Corporation | Sustained release small molecule drug formulation |
EP1948810A4 (en) * | 2005-11-04 | 2010-06-30 | Biosyntech Canada Inc | COMPOSITION AND METHOD USING CHITOSAN FOR THE EFFICIENT ADMINISTRATION OF NUCLEIC ACIDS TO CELLS |
US20090048667A1 (en) * | 2005-11-16 | 2009-02-19 | Tokai University Educational System | Controlled Drug-Release Composition and Drug-Releasable Medical Device |
BRPI0620063B8 (pt) * | 2005-12-22 | 2021-05-25 | Novartis Ag | composição farmacêutica de liberação sustentada na forma de micropartículas, uso, e kit de administração |
US20070149640A1 (en) * | 2005-12-28 | 2007-06-28 | Sasa Andjelic | Bioabsorbable polymer compositions exhibiting enhanced crystallization and hydrolysis rates |
US8236904B2 (en) | 2005-12-28 | 2012-08-07 | Ethicon, Inc. | Bioabsorbable polymer compositions exhibiting enhanced crystallization and hydrolysis rates |
US20070178138A1 (en) * | 2006-02-01 | 2007-08-02 | Allergan, Inc. | Biodegradable non-opthalmic implants and related methods |
ES2351527T3 (es) | 2006-05-30 | 2011-02-07 | Intarcia Therapeutics, Inc | Modulador de flujo en dos piezas con conducto interno para un sistema osmótico de administración. |
US20070298073A1 (en) * | 2006-06-23 | 2007-12-27 | Allergan, Inc. | Steroid-containing sustained release intraocular implants and related methods |
US8802128B2 (en) * | 2006-06-23 | 2014-08-12 | Allergan, Inc. | Steroid-containing sustained release intraocular implants and related methods |
EP2359808B1 (en) | 2006-08-09 | 2013-05-22 | Intarcia Therapeutics, Inc | Osmotic delivery systems and piston assemblies |
US8969415B2 (en) * | 2006-12-01 | 2015-03-03 | Allergan, Inc. | Intraocular drug delivery systems |
US8846073B2 (en) | 2006-12-19 | 2014-09-30 | Allergan, Inc. | Low temperature processes for making cyclic lipid implants for intraocular use |
EP2157967B1 (en) | 2007-04-23 | 2013-01-16 | Intarcia Therapeutics, Inc | Suspension formulations of insulinotropic peptides and uses thereof |
HUE030789T2 (en) | 2007-05-18 | 2017-06-28 | Durect Corp | Improved depot formulation |
BRPI0811319A2 (pt) | 2007-05-25 | 2015-02-10 | Tolmar Therapeutics Inc | Composição fluida, método de formação de uma composição fluida, implante biodegrádavel formado in situ, método de formação de um implante biodegradável in situ, kit, implante e método de trataento |
WO2008149364A2 (en) * | 2007-06-07 | 2008-12-11 | Sarah Brenner | Methods for diagnosing hypersensitivity reactions |
US7923021B2 (en) * | 2007-07-24 | 2011-04-12 | University Of Memphis Research Foundation | Local delivery method and composition |
RU2343908C1 (ru) * | 2007-09-05 | 2009-01-20 | Руслан Дмитриевич Илюк | Средство для профилактики и лечения алкоголизма и способ его применения |
US8470360B2 (en) * | 2008-04-18 | 2013-06-25 | Warsaw Orthopedic, Inc. | Drug depots having different release profiles for reducing, preventing or treating pain and inflammation |
JP2011503183A (ja) * | 2007-11-13 | 2011-01-27 | サーモディクス ファーマシューティカルズ, インコーポレイテッド | 薬物送達のプラットホームとしての粘稠なターポリマー |
ES2718612T3 (es) | 2007-12-20 | 2019-07-03 | Evonik Corp | Procedimiento para preparar micropartículas que tienen un bajo volumen de disolvente residual |
AU2013201877B2 (en) * | 2008-01-30 | 2015-01-29 | Novartis Ag | Sustained release formulation comprising octreotide and three linear polylactide-co-glycolide polymers |
AU2009209594A1 (en) * | 2008-01-30 | 2009-08-06 | Novartis Ag | Sustained release formulation comprising octreotide and three linear polylactide-co-glycolide polymers |
CA2726861C (en) | 2008-02-13 | 2014-05-27 | Intarcia Therapeutics, Inc. | Devices, formulations, and methods for delivery of multiple beneficial agents |
US8889173B2 (en) * | 2008-04-18 | 2014-11-18 | Warsaw Orthopedic, Inc. | Alpha adrenergic receptor agonists for treatment of pain and/or inflammation |
US7993666B2 (en) * | 2008-04-18 | 2011-08-09 | Warsaw Orthopedic, Inc. | Methods and compositions for treating pain comprising a statin |
US20090263456A1 (en) * | 2008-04-18 | 2009-10-22 | Warsaw Orthopedic, Inc. | Methods and Compositions for Reducing Preventing and Treating Adhesives |
US8524267B2 (en) * | 2008-04-18 | 2013-09-03 | Warsaw Orthopedic, Inc. | Dexamethasone formulations in a biodegradable material |
US8883768B2 (en) * | 2008-04-18 | 2014-11-11 | Warsaw Orthopedic, Inc. | Fluocinolone implants to protect against undesirable bone and cartilage destruction |
US8956641B2 (en) * | 2008-04-18 | 2015-02-17 | Warsaw Orthopedic, Inc. | Alpha adrenergic receptor agonists for treatment of inflammatory diseases |
US9072727B2 (en) * | 2008-04-18 | 2015-07-07 | Warsaw Orthopedic, Inc. | Alpha adrenergic receptor agonists for treatment of degenerative disc disease |
US8846068B2 (en) * | 2008-04-18 | 2014-09-30 | Warsaw Orthopedic, Inc. | Methods and compositions for treating post-operative pain comprising a local anesthetic |
US8846770B2 (en) * | 2008-06-18 | 2014-09-30 | Otonomy, Inc. | Controlled release aural pressure modulator compositions and methods for the treatment of OTIC disorders |
CN104248623B (zh) * | 2008-09-04 | 2020-04-03 | 安米林药品有限责任公司 | 使用非水性载体的持续释放制剂 |
US9623222B2 (en) * | 2008-10-30 | 2017-04-18 | Warsaw Orthopedic, Inc. | Drug depot with anchor |
US9095506B2 (en) | 2008-11-17 | 2015-08-04 | Allergan, Inc. | Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof |
US20100151033A1 (en) * | 2008-12-15 | 2010-06-17 | Novartis Ag | Octreotide depot formulation with constantly high exposure levels |
US8951546B2 (en) | 2008-12-23 | 2015-02-10 | Surmodics Pharmaceuticals, Inc. | Flexible implantable composites and implants comprising same |
US8974808B2 (en) * | 2008-12-23 | 2015-03-10 | Surmodics, Inc. | Elastic implantable composites and implants comprising same |
US9415197B2 (en) | 2008-12-23 | 2016-08-16 | Surmodics, Inc. | Implantable suction cup composites and implants comprising same |
US20100158978A1 (en) * | 2008-12-23 | 2010-06-24 | Peter Markland | Bioactive spray coating compositions and methods of making and uses thereof |
US20100168807A1 (en) * | 2008-12-23 | 2010-07-01 | Burton Kevin W | Bioactive terpolymer compositions and methods of making and using same |
US20100228097A1 (en) * | 2009-03-04 | 2010-09-09 | Warsaw Orthopedic, Inc. | Methods and compositions to diagnose pain |
US20100247606A1 (en) * | 2009-03-25 | 2010-09-30 | Allergan, Inc. | Intraocular sustained release drug delivery systems and methods for treating ocular conditions |
EP2475396A4 (en) * | 2009-09-10 | 2013-10-16 | Univ Pittsburgh | ARTIFICIAL MICROPARTICLES FOR THE ADMINISTRATION OF MACROMOLECULES |
EP3323423B1 (en) | 2009-09-28 | 2020-06-17 | Intarcia Therapeutics, Inc | Rapid establishment and/or termination of substantial steady-state drug delivery |
US20110097380A1 (en) * | 2009-10-28 | 2011-04-28 | Warsaw Orthopedic, Inc. | Clonidine formulations having antimicrobial properties |
MX361709B (es) | 2009-11-09 | 2018-12-07 | Allergan Inc | Composiciones y metodos para estimular el crecimiento del cabello. |
US9993441B2 (en) | 2009-12-30 | 2018-06-12 | Surmodics, Inc. | Controlled release matrix barrier structure for subcutaneous medical devices |
DK3085358T3 (en) * | 2010-01-22 | 2018-02-05 | Allergan Inc | INTRAKAMERAL IMPLANTS WITH DEPOT PREPARATION |
WO2011133370A1 (en) * | 2010-04-23 | 2011-10-27 | Medtronic, Inc. | Shelf stable pharmaceutical depot |
GB2513267B (en) * | 2010-06-08 | 2015-03-18 | Rb Pharmaceuticals Ltd | Injectable flowable composition comprising buprenorphine |
GB2513060B (en) | 2010-06-08 | 2015-01-07 | Rb Pharmaceuticals Ltd | Microparticle buprenorphine suspension |
US9272044B2 (en) | 2010-06-08 | 2016-03-01 | Indivior Uk Limited | Injectable flowable composition buprenorphine |
WO2012030819A1 (en) | 2010-08-30 | 2012-03-08 | Surmodics Pharmaceuticals, Inc. | Terpolymers as pressure-sensitive adhesives |
CA2810842C (en) * | 2010-09-09 | 2018-06-26 | Micell Technologies, Inc. | Macrolide dosage forms |
US20120208755A1 (en) | 2011-02-16 | 2012-08-16 | Intarcia Therapeutics, Inc. | Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers |
WO2012125914A1 (en) * | 2011-03-16 | 2012-09-20 | University Of Delaware | Injectable delivery system for heparan sulfate binding growth factors |
CN102133180B (zh) * | 2011-03-18 | 2016-03-09 | 黄芳 | 一种甾体5α-还原酶抑制剂长效注射制剂及其制备方法 |
US9005634B2 (en) | 2011-04-13 | 2015-04-14 | Medtronic, Inc. | Shelf stable pharmaceutical depot |
JP5728128B2 (ja) * | 2011-04-25 | 2015-06-03 | シャントン ルーイエ ファーマシューティカル カンパニー リミテッド | リスペリドン徐放性ミクロスフェア組成物 |
US8951996B2 (en) * | 2011-07-28 | 2015-02-10 | Lipocine Inc. | 17-hydroxyprogesterone ester-containing oral compositions and related methods |
ES2715562T3 (es) * | 2011-12-15 | 2019-06-04 | Alkermes Pharma Ireland Ltd | Profármacos de compuestos de amina secundaria |
WO2013162270A1 (ko) * | 2012-04-24 | 2013-10-31 | 서울대학교산학협력단 | 약물의 제어 방출이 가능한 유방 보형물 및 이의 제조방법 |
US8822423B2 (en) * | 2012-05-17 | 2014-09-02 | Janssen Biotech, Inc. | Affinity peptides toward infliximab |
ES2709351T3 (es) | 2012-09-27 | 2019-04-16 | Allergan Inc | Sistemas de administración de fármacos biodegradables para la liberación sostenida de proteínas |
BR112015019546A2 (pt) | 2013-02-15 | 2017-07-18 | Allergan Inc | implante de distribuição de drogas prolongado |
BR112015022023B1 (pt) | 2013-03-11 | 2022-12-06 | Durect Corporation | Composição de liberação controlada injetável compreendendo transportador líquido de alta viscosidade |
US20140308352A1 (en) | 2013-03-11 | 2014-10-16 | Zogenix Inc. | Compositions and methods involving polymer, solvent, and high viscosity liquid carrier material |
WO2014143635A1 (en) * | 2013-03-15 | 2014-09-18 | Heron Therapeutics, Inc. | Compositions of a polyorthoester and an aprotic solvent |
US9492316B2 (en) | 2013-10-31 | 2016-11-15 | Allergan, Inc. | Prostamide-containing intraocular implants and methods of use thereof |
EP3079668A1 (en) | 2013-12-09 | 2016-10-19 | Durect Corporation | Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same |
JP6247400B2 (ja) * | 2013-12-31 | 2017-12-13 | ペベエベ・エスア | 身体再建及び身体成形における使用のための制御放出脂肪酸組成物 |
GB201404139D0 (en) | 2014-03-10 | 2014-04-23 | Rb Pharmaceuticals Ltd | Sustained release buprenorphine solution formulations |
US9889085B1 (en) | 2014-09-30 | 2018-02-13 | Intarcia Therapeutics, Inc. | Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c |
WO2016071767A1 (en) | 2014-11-07 | 2016-05-12 | Indivior Uk Limited | Buprenorphine dosing regimens |
MA44390A (fr) | 2015-06-03 | 2019-01-23 | Intarcia Therapeutics Inc | Systèmes de mise en place et de retrait d'implant |
EP3324890A4 (en) * | 2015-07-23 | 2019-06-19 | Allergan, Inc. | GLACO-TREATMENT VIA INTRAKAMERAL EYE IMPLANTS |
SG11201810102SA (en) | 2016-05-16 | 2018-12-28 | Intarcia Therapeutics Inc | Glucagon-receptor selective polypeptides and methods of use thereof |
USD860451S1 (en) | 2016-06-02 | 2019-09-17 | Intarcia Therapeutics, Inc. | Implant removal tool |
USD840030S1 (en) | 2016-06-02 | 2019-02-05 | Intarcia Therapeutics, Inc. | Implant placement guide |
MX2018016424A (es) | 2016-06-30 | 2019-08-12 | Durect Corp | Formulaciones de deposito. |
US10682340B2 (en) | 2016-06-30 | 2020-06-16 | Durect Corporation | Depot formulations |
CN110225762A (zh) | 2017-01-03 | 2019-09-10 | 因塔西亚制药公司 | 包括glp-1受体激动剂的连续施用和药物的共同施用的方法 |
AU2018285975B2 (en) | 2017-06-13 | 2023-11-16 | The University Of British Columbia | Polymeric paste compositions for drug delivery |
US10646484B2 (en) | 2017-06-16 | 2020-05-12 | Indivior Uk Limited | Methods to treat opioid use disorder |
JP2021521270A (ja) * | 2018-04-06 | 2021-08-26 | アンマ セラピューティクス インコーポレイテッドAmma Therapeutics, Inc. | 治療剤の制御放出用組成物 |
KR20220140711A (ko) | 2020-01-13 | 2022-10-18 | 듀렉트 코퍼레이션 | 불순물이 감소된 지속 방출 약물 전달 시스템 및 관련 방법 |
CN111548482B (zh) * | 2020-04-02 | 2022-09-13 | 复旦大学 | 一氧化氮供体修饰的共聚物、包含其的缓释制剂及其制备方法与应用 |
EP4362932A1 (en) * | 2021-06-30 | 2024-05-08 | The University of North Carolina at Chapel Hill | Injectable, biodegradable and removable polymer based drug suspension for ultra-long-acting drug delivery |
Family Cites Families (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3797492A (en) * | 1972-12-27 | 1974-03-19 | Alza Corp | Device for dispensing product with directional guidance member |
US3887790A (en) * | 1974-10-07 | 1975-06-03 | Vernon H Ferguson | Wrap-around electric resistance heater |
US3987790A (en) | 1975-10-01 | 1976-10-26 | Alza Corporation | Osmotically driven fluid dispenser |
US4008719A (en) * | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
JPS5933320B2 (ja) * | 1981-04-03 | 1984-08-15 | 株式会社東芝 | 光学的情報記録媒体 |
US4443340A (en) * | 1981-10-09 | 1984-04-17 | Betz Laboratories, Inc. | Control of iron induced fouling in water systems |
US4985404A (en) * | 1984-10-04 | 1991-01-15 | Monsanto Company | Prolonged release of biologically active polypeptides |
US4865845A (en) * | 1986-03-21 | 1989-09-12 | Alza Corporation | Release rate adjustment of osmotic or diffusional delivery devices |
US4853218A (en) * | 1987-02-24 | 1989-08-01 | Schering Corporation | Zinc-protamine-alpha interferon complex |
US4938763B1 (en) * | 1988-10-03 | 1995-07-04 | Atrix Lab Inc | Biodegradable in-situ forming implants and method of producing the same |
US5085866A (en) * | 1988-12-02 | 1992-02-04 | Southern Research Institute | Method of producing zero-order controlled-released devices |
US5057318A (en) * | 1988-12-13 | 1991-10-15 | Alza Corporation | Delivery system for beneficial agent over a broad range of rates |
US5059423A (en) * | 1988-12-13 | 1991-10-22 | Alza Corporation | Delivery system comprising biocompatible beneficial agent formulation |
US5324519A (en) * | 1989-07-24 | 1994-06-28 | Atrix Laboratories, Inc. | Biodegradable polymer composition |
US5112614A (en) * | 1989-09-14 | 1992-05-12 | Alza Corporation | Implantable delivery dispenser |
US5234693A (en) * | 1990-07-11 | 1993-08-10 | Alza Corporation | Delivery device with a protective sleeve |
US5234692A (en) * | 1990-07-11 | 1993-08-10 | Alza Corporation | Delivery device with a protective sleeve |
US5151093A (en) * | 1990-10-29 | 1992-09-29 | Alza Corporation | Osmotically driven syringe with programmable agent delivery |
US5620700A (en) * | 1990-10-30 | 1997-04-15 | Alza Corporation | Injectable drug delivery system and method |
GB9027422D0 (en) * | 1990-12-18 | 1991-02-06 | Scras | Osmotically driven infusion device |
US5137727A (en) * | 1991-06-12 | 1992-08-11 | Alza Corporation | Delivery device providing beneficial agent stability |
US5288214A (en) * | 1991-09-30 | 1994-02-22 | Toshio Fukuda | Micropump |
EP0572675B1 (en) * | 1991-12-19 | 1999-09-22 | Mitsui Chemicals, Inc. | Polyhydroxy carboxylic acid and production thereof |
US5456679A (en) * | 1992-02-18 | 1995-10-10 | Alza Corporation | Delivery devices with pulsatile effect |
US5209746A (en) * | 1992-02-18 | 1993-05-11 | Alza Corporation | Osmotically driven delivery devices with pulsatile effect |
US5308348A (en) * | 1992-02-18 | 1994-05-03 | Alza Corporation | Delivery devices with pulsatile effect |
US5656297A (en) * | 1992-03-12 | 1997-08-12 | Alkermes Controlled Therapeutics, Incorporated | Modulated release from biocompatible polymers |
GB9211268D0 (en) * | 1992-05-28 | 1992-07-15 | Ici Plc | Salts of basic peptides with carboxyterminated polyesters |
US5242910A (en) * | 1992-10-13 | 1993-09-07 | The Procter & Gamble Company | Sustained release compositions for treating periodontal disease |
ES2151541T3 (es) * | 1992-12-02 | 2001-01-01 | Alkermes Inc | Microesferas que contienen hormona del crecimiento de liberacion prolongada. |
US5468253A (en) * | 1993-01-21 | 1995-11-21 | Ethicon, Inc. | Elastomeric medical device |
CA2176716C (en) | 1993-11-19 | 2009-04-07 | Ramstack, J. Michael | Preparation of biodegradable microparticles containing a biologically active agent |
US5556905A (en) * | 1994-03-30 | 1996-09-17 | Reilly Industries, Inc. | Physically-modified degradable thermoplastic compositions |
ATE209907T1 (de) * | 1994-04-08 | 2001-12-15 | Atrix Lab Inc | Flüssige mittel zur wirkstoffabgabe |
US5626862A (en) * | 1994-08-02 | 1997-05-06 | Massachusetts Institute Of Technology | Controlled local delivery of chemotherapeutic agents for treating solid tumors |
US5639851A (en) * | 1995-10-02 | 1997-06-17 | Ethicon, Inc. | High strength, melt processable, lactide-rich, poly(lactide-CO-P-dioxanone) copolymers |
US6113624A (en) * | 1995-10-02 | 2000-09-05 | Ethicon, Inc. | Absorbable elastomeric polymer |
ATE318580T1 (de) * | 1996-12-20 | 2006-03-15 | Alza Corp | Gelzusammensetzungen und verfahren |
US6193991B1 (en) * | 1997-10-29 | 2001-02-27 | Atul J. Shukla | Biodegradable delivery systems of biologically active substances |
WO2000074650A2 (en) | 1999-06-04 | 2000-12-14 | Alza Corporation | Implantable gel compositions and method of manufacture |
AU2001245346A1 (en) * | 2000-06-28 | 2002-01-08 | Atul J. Shukla | Biodegradable vehicles and delivery systems of biologically active substances |
WO2002038185A2 (en) | 2000-11-13 | 2002-05-16 | Atrix Laboratories, Inc. | Injectable sustained release delivery system with loperamide |
WO2002058670A1 (en) | 2001-01-25 | 2002-08-01 | Euroceltique S.A. | Local anesthetic, and method of use |
DE60231862D1 (de) | 2001-02-23 | 2009-05-20 | Genentech Inc | Erodierbare polymere zur injektion |
KR20040065153A (ko) * | 2001-11-14 | 2004-07-21 | 알자 코포레이션 | 주입가능한 데포 조성물 |
US20030170289A1 (en) * | 2001-11-14 | 2003-09-11 | Guohua Chen | Injectable depot compositions and uses thereof |
DE60239556D1 (de) * | 2001-11-14 | 2011-05-05 | Durect Corp | Katheterinjizierbare depotzusammensetzungen und deren verwendung |
US20040001889A1 (en) * | 2002-06-25 | 2004-01-01 | Guohua Chen | Short duration depot formulations |
AR039729A1 (es) * | 2002-06-25 | 2005-03-09 | Alza Corp | Formulaciones de deposito de corta duracion |
MXPA05001244A (es) * | 2002-07-31 | 2005-06-08 | Alza Corp | Composiciones de deposito de polimero multimodal inyectable y usos de las mismas. |
AU2002359397B2 (en) * | 2002-07-31 | 2009-01-29 | Durect Corporation | Injectable depot compositions and uses thereof |
US20050281879A1 (en) * | 2003-11-14 | 2005-12-22 | Guohua Chen | Excipients in drug delivery vehicles |
US20050106214A1 (en) * | 2003-11-14 | 2005-05-19 | Guohua Chen | Excipients in drug delivery vehicles |
-
2003
- 2003-11-04 RU RU2005117164/15A patent/RU2355385C2/ru active
- 2003-11-04 BR BR0315304-5A patent/BR0315304A/pt not_active IP Right Cessation
- 2003-11-04 JP JP2004551819A patent/JP2006508127A/ja active Pending
- 2003-11-04 US US10/701,939 patent/US7368126B2/en not_active Expired - Fee Related
- 2003-11-04 EP EP03786595A patent/EP1581181B1/en not_active Expired - Lifetime
- 2003-11-04 CA CA2504608A patent/CA2504608C/en not_active Expired - Fee Related
- 2003-11-04 AU AU2003295409A patent/AU2003295409B2/en not_active Ceased
- 2003-11-04 DE DE60325511T patent/DE60325511D1/de not_active Expired - Lifetime
- 2003-11-04 MX MXPA05004927A patent/MXPA05004927A/es unknown
- 2003-11-04 WO PCT/US2003/035416 patent/WO2004043432A2/en active Application Filing
- 2003-11-04 NZ NZ539810A patent/NZ539810A/en unknown
- 2003-11-04 KR KR1020057008166A patent/KR20050088288A/ko not_active Application Discontinuation
- 2003-11-04 CN CNA2003801039719A patent/CN1713890A/zh active Pending
- 2003-11-04 PL PL377333A patent/PL377333A1/pl not_active Application Discontinuation
- 2003-11-04 AT AT03786595T patent/ATE418323T1/de not_active IP Right Cessation
- 2003-11-05 MY MYPI20034232A patent/MY140155A/en unknown
- 2003-11-06 TW TW092131019A patent/TW200503774A/zh unknown
- 2003-11-06 UY UY28067A patent/UY28067A1/es not_active Application Discontinuation
- 2003-11-06 AR ARP030104083A patent/AR041913A1/es not_active Application Discontinuation
- 2003-11-06 CL CL200302277A patent/CL2003002277A1/es unknown
- 2003-11-06 PE PE2003001127A patent/PE20040675A1/es not_active Application Discontinuation
-
2005
- 2005-05-05 MA MA28260A patent/MA27523A1/fr unknown
- 2005-06-01 NO NO20052635A patent/NO20052635L/no not_active Application Discontinuation
- 2005-06-02 ZA ZA200504529A patent/ZA200504529B/en unknown
- 2005-06-06 EC EC2005005838A patent/ECSP055838A/es unknown
- 2005-12-22 EC EC2005006249A patent/ECSP056249A/es unknown
-
2006
- 2006-04-04 HK HK06104121.8A patent/HK1085387A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
RU2355385C2 (ru) | 2009-05-20 |
KR20050088288A (ko) | 2005-09-05 |
HK1085387A1 (en) | 2006-08-25 |
US20040151753A1 (en) | 2004-08-05 |
RU2005117164A (ru) | 2006-01-20 |
CA2504608C (en) | 2013-01-08 |
NZ539810A (en) | 2008-03-28 |
CA2504608A1 (en) | 2004-05-27 |
JP2006508127A (ja) | 2006-03-09 |
MA27523A1 (fr) | 2005-09-01 |
ATE418323T1 (de) | 2009-01-15 |
US7368126B2 (en) | 2008-05-06 |
WO2004043432A2 (en) | 2004-05-27 |
ZA200504529B (en) | 2006-08-30 |
BR0315304A (pt) | 2005-08-16 |
AU2003295409B2 (en) | 2010-02-11 |
TW200503774A (en) | 2005-02-01 |
EP1581181B1 (en) | 2008-12-24 |
AR041913A1 (es) | 2005-06-01 |
CL2003002277A1 (es) | 2005-05-06 |
DE60325511D1 (de) | 2009-02-05 |
EP1581181A2 (en) | 2005-10-05 |
WO2004043432A3 (en) | 2004-07-08 |
ECSP055838A (es) | 2005-09-20 |
PE20040675A1 (es) | 2004-09-25 |
ECSP056249A (es) | 2006-10-17 |
NO20052635D0 (no) | 2005-06-01 |
NO20052635L (no) | 2005-07-20 |
AU2003295409A1 (en) | 2004-06-03 |
MY140155A (en) | 2009-11-30 |
MXPA05004927A (es) | 2005-09-08 |
CN1713890A (zh) | 2005-12-28 |
PL377333A1 (pl) | 2006-01-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY28067A1 (es) | Formulaciones de deposito de liberacion controlada | |
MXPA05013003A (es) | Composiciones de deposito elastomerico implantables, usos de las mismas y metodo para elaboracion. | |
AR040753A1 (es) | Composiciones de deposito de polimeros multimodales injectables y usos de las mismas | |
UY28285A1 (es) | Péliculas consumibles por vía oral que se disuelven rápidamente, que contienen un edulcorante | |
CR6656A (es) | Forma de dosificacion de farmacos accionada por un hidrogel | |
ES2171971T3 (es) | Producto limpiador y de tratamiento con almidon. | |
AR055552A1 (es) | Preparacion topica refrescante para parches y metodos para utilizar la misma | |
AR052545A1 (es) | Suspension no acuosa inyectable | |
AR044926A1 (es) | Sistema de suministro de farmacos gelificante in situ | |
AR063621A1 (es) | Matriz polimerica insoluble en agua para la administracion de farmacos | |
AR048064A1 (es) | Dispositivo de colageno y metodo para preparar el mismo | |
CO5060481A1 (es) | Suministro de agente activo aerosolizado modulado con resistencia de flujo | |
CO5210862A1 (es) | Formas de dosificacion y metodos para proporcionar efectiva terapia de reboxetina con dosificacion de una vez al dia | |
AR048017A1 (es) | Composicion y metodo para aumentar la biodisponibilidad | |
MX9207402A (es) | Dispositivo osmotico para surtir un agente benefico a la cavidad oral. | |
RS51764B (en) | TRANSDERMAL PHARMACEUTICAL COMPOSITION | |
AR045975A1 (es) | Formas de liberacion sostenida de anestesicos para el tratamiento del dolor | |
SG156624A1 (en) | Organo-gel formulations for therapeutic applications | |
BRPI0509332A (pt) | implantes oculares biodegradáveis com caracterìsticas de liberação a longo prazo | |
AR044964A1 (es) | Formulaciones para microproyecciones recubiertas que contienen contra-iones no volatiles | |
PE20110010A1 (es) | Formulaciones liquidas de fenilefrina | |
CL2004000931A1 (es) | Pelicula consumible adaptada para adherirse y disolverse en la cavidad bucal que comprende un almidon modificado y un agente farmaceuticamente activo. | |
AR033418A1 (es) | Preparado farmaceutico mucoadhesivo desintegrable para la administracion de sustancia activa en medicina veterinaria y humana | |
AR109263A2 (es) | Composición que comprende moxidectina | |
UY25544A1 (es) | Forma de dosificación de nefazodona |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20150506 |